Global /Australia /Healthcare /Drug Manufacturers - General /PAB

Patrys Ltd.

PAB

• ASX: PAB • Delayed

0.0290AUD -6.5%

0.0207 USD

As of 5 June 2026, Patrys Ltd. has a market cap of $11.84M USD, ranking #40364 globally and #1278 in Australia. It ranks #3595 in the Healthcare sector, and #1172 in the Drug Manufacturers - General industry.

Global Rank

40364

Country Rank

1278

Sector Rank

3595

Industry Rank

1172

Key Stats

Market Cap

$11.84MUSD

16.6M AUD

Enterprise Value

$10.49MUSD

14.69M AUD

Revenue (TTM)

$71.63KUSD

100.38K AUD

EBITDA (TTM)

-$2.97MUSD

-4.16M AUD

Net Income (TTM)

-$3.22MUSD

-4.51M AUD

PS Ratio

165.3

PB Ratio

11.1

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Samantha South open_in_new

Employees

Founded

2006

Website

patrys.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-6.5%	24%	6.9%	3.3%	-23%	11%	-14%	-83%	-90%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	PAB Patrys Ltd ISIN: AU000000PAB9 Shares Out.: Shares Outstanding: 666.614M¹ Shares Float: 660.495M² TV: TradingView: ASX: PAB SA: Stock Analysis: ASX: PAB YF: Yahoo Finance: PAB.AX GF: Google Finance: ASX: PAB BA: Barron's: PAB MS: Morningstar: XASX: PAB	0.0290 AUD	TV: TradingView: ASX: PAB SA: Stock Analysis: ASX: PAB YF: Yahoo Finance: PAB.AX GF: Google Finance: ASX: PAB BA: Barron's: PAB MS: Morningstar: XASX: PAB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Patrys Ltd.

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 193K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 8K%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 3K%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 3K%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 2K%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 1K%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 6M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 5M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 3M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 3M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 2M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 2M%	20.5	Switzerland

chevron_leftBack